MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cascieri, M. A.
Right arrow Articles by Liang, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cascieri, M. A.
Right arrow Articles by Liang, T.

Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422

MA Cascieri, HG Bull, RA Mumford, AA Patchett, NA Thornberry and T Liang

The hydrolysis of substance P is catalyzed by purified rabbit lung angiotensin-converting enzyme (peptidyldipeptide hydrolase, EC 3.4.15.1). The kcat/Km for the reaction at 37 degrees is 3.3 +/- 0.3 X 10(3) M-1 sec-1, which is 60 times less than that which has been reported for the hydrolysis of angiotensin I. The initial site of hydrolysis is the antipenultimate peptide bond, which generates the tripeptide amide (Gly-Leu-Met-NH2). This hydrolysis is inhibited by the angiotensin-converting enzyme inhibitors captopril, MK-422, and EDTA, and is dependent on the concentration of chloride ion. Both captopril and MK-422 potentiate the substance P-induced stimulation of salivation in rats. Thus, angiotensin-converting enzyme may be one of the enzymes that degrade substance P in vivo.

Volume 25, Issue 2, pp. 287-293, 03/01/1984
Copyright © 1984 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
N. Naqvi, K. Liu, R. M. Graham, and A. Husain
Molecular Basis of Exopeptidase Activity in the C-terminal Domain of Human Angiotensin I-converting Enzyme: INSIGHTS INTO THE ORIGINS OF ITS EXOPEPTIDASE ACTIVITY
J. Biol. Chem., February 25, 2005; 280(8): 6669 - 6675.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
S.-C. Lee, S. W. Park, D.-K. Kim, S. H. Lee, and K. P. Hong
Iron Supplementation Inhibits Cough Associated With ACE Inhibitors
Hypertension, August 1, 2001; 38(2): 166 - 170.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
E. N. Patak, S. Ziccone, M. E. Story, A. J. Fleming, A. Lilley, and J. N. Pennefather
Activation of neurokinin NK2 receptors by tachykinin peptides causes contraction of uterus in pregnant women near term
Mol. Hum. Reprod., June 1, 2000; 6(6): 549 - 554.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. J. Brown and D. E. Vaughan
Angiotensin-Converting Enzyme Inhibitors
Circulation, April 14, 1998; 97(14): 1411 - 1420.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
W. E. Haefeli, L. Linder, and T. F. Luscher
Quinaprilat Induces Arterial Vasodilation Mediated by Nitric Oxide in Humans
Hypertension, October 1, 1997; 30(4): 912 - 917.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1984 by the American Society for Pharmacology and Experimental Therapeutics